drugset / Trial / NCT05598281

Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants

NCT05598281

Phase 1 Completed 14 enrolled Amgen
NaSingle-groupOpen-labelBasic science

Summary

The primary objective of the study is to evaluate the PK of digoxin administered alone and in combination with AMG 510 in healthy participants.

Timeline

Start
2019-11-05
Primary completion
2019-11-19
Completion
2019-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.5 mg Oral
Subject Sotorasib Small molecule 960 mg Oral

Indications

No indication recorded.